Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Opening Session Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Apr
17
Today In Oncology
Sequential or Concurrent Radiotherapy and Immunotherapy in Advanced Newly Diagnosed or Refractory NSCLC
Romiplostim for Chemotherapy-Induced Thrombocytopenia
AYA Cancer Survivors and Risk for Earlier Subsequent Primary Neoplasms
Bispecific Antibody Shows Deep Remission in Patients With Relapsed/Refractory Follicular Lymphoma
Is Standard of Care Optimal for the Individual Patient?
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo